Details

---

Manufacturer
BAXTER ONCOLOGY GMBH(GERMANY)
Registraction Number
MAL20101997ACRZ

Here’s the information about VIDAZA Powder for Suspension for Injection 100mg/Vial:

Content

Active Ingredient: Azacitidine (100 mg per vial), an antineoplastic agent.
Excipients: Includes mannitol and other stabilizing agents.

Indication

Used for the treatment of:
Myelodysplastic syndromes (MDS).
Chronic myelomonocytic leukemia (CMML).
Acute myeloid leukemia (AML) in certain cases.

Instruction

Preparation:
Reconstitute the powder with 4 mL of sterile water for injection.
Shake vigorously to form a uniform suspension.
Dosage:
The dose is individualized based on body surface area and the specific condition being treated.
Typically administered subcutaneously or intravenously.
Administration:
Administered by healthcare professionals.
Infusion or injection schedules vary depending on the treatment protocol.
Precautions:
Avoid use in patients with hypersensitivity to azacitidine or its excipients.
Monitor for potential side effects such as nausea, fatigue, or low blood cell counts.
Store below 30°C and protect from light.